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Abstract 
The neuropeptide orexin-A (OXA) has a neuroprotective effect, acting as an anti-
apoptotic factor in response to multiple stimuli. Apoptosis induced by endoplasmic 
reticulum stress (ERS) underlies oxygen-glucose deprivation and reoxygenation 
(OGD/R)-induced cell damage, an in vitro model of ischemia/reperfusion injury. 
However, that OXA inhibits ERS-induced apoptosis in the OGD/R model has not 
been reported. In the present study, we investigated the neuroprotective effect of OXA 
(0.1 μM) on OGD/R-induced damage in the human neuroblastoma cell line SH-SY5Y. 
After OXA treatment following 4 h oxygen-glucose deprivation (OGD) and then 4 h 
reoxygenation (R), cell morphology, viability, and apoptosis were analyzed by 
histology, Cell Counting Kit-8 assay, and flow cytometry, respectively. Western 
blotting was used to measure expression levels of ERS- and apoptosis-related proteins. 
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To determine signaling pathways involved in OXA-mediated neuroprotection, the Gi 
pathway inhibitor pertussis toxin (PTX; 100 ng/mL) and PI3K inhibitor LY294002 
(LY; 10 μM) were added. In addition, in order to prove the specificity of these 
characteristics, the OXA antagonist Suvorexant (DORA; Ki of 0.55 nM and 0.35 nM 
for OX1R and OX2R) was used for intervention. Our results showed that OGD/R 
induced cell damage, manifested as morphological changes and a significant decrease 
in viability. Furthermore, Western blotting detected an increase in ERS-related 
proteins GRP78, p-IRE1α, p-JNK, and Cleaved caspase-12, as well as apoptosis-
related proteins Cleaved caspase-3 and Bax, and a decrease in the anti-apoptosis 
factor Bcl-2. OXA intervention alleviated the degree of cellular damage, and protein 
expression was also reversed. In addition, the protective effect of OXA was reduced 
by adding PTX and LY. Meanwhile, after the use of DORA, changes in the expression 
of related proteins were detected, and it was found that the protective effect of OXA 
was weakened. Collectively, our results indicate that OXA has a neuroprotective 
effect on OGD/R-induced cell damage by inhibiting ERS-induced apoptosis through 
the combined action of Gi and PI3K signaling pathways. These findings help to 
clarify the mechanism underlying the neuroprotective action of OXA, which should 
aid the development of further candidate drugs, and provide a new therapeutic 
direction for the treatment of ischemic stroke. 
Keywords: Orexin-A (OXA); neuroprotection; oxygen-glucose deprivation and 
reoxygenation (OGD/R); endoplasmic reticulum stress (ERS); apoptosis  
Abbreviations: 
CCK-8Cell Counting Kit-8 
DORA Suvorexant 
ERS endoplasmic reticulum stress 
GRP glucose-regulated protein 
HE staining hematoxylin-eosin staining 
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I/R ischemia/reperfusion 
LY LY294002 
OXA Orexin-A 
OGD/R oxygen-glucose deprivation and reoxygenation 
OD optical density;  
PTX pertussis toxin. 
 
1. Introduction 
Ischemic stroke is a serious global health problem. In recent years, research has 
focused on various measures to improve cerebral blood circulation, including 
thrombolytic, antiplatelet, and anticoagulation therapies, vasodilation, and 
administration of neuroprotective drugs. At present, the key to alleviating ischemic 
brain injury is believed to be early recovery of blood flow, and reperfusion therapy 
such as thrombolysis is currently the most effective clinical treatment for cerebral 
ischemia. However, reperfusion therapy is limited by the time taken to reperfuse 
ischemic tissues and the risk of reperfusion injury [1]. In the treatment of ischemic 
stroke, the urgent problems to be solved are how best to stimulate endogenous 
protection and enhance the resistance of nerve cells to ischemia and hypoxia. 
Within eukaryotic cells, the endoplasmic reticulum (ER) regulates protein 
folding, Ca2+ homeostasis, and the stress response, and is thus very sensitive to stress 
stimuli. ER dysfunction can be induced by ischemia and hypoxia, glucose/nutrient 
deficiency, ATP depletion, free radicals, and Ca2+ homeostasis disturbance, all of 
which can ultimately trigger the response known as ER stress (ERS) [2]. ERS is 
mainly characterized by the up-regulation of glucose-regulated proteins (GRPs), 
calmodulin, and protein folding enzymes, and activation of apoptosis-promoting 
factors such as caspase-3 and caspase-12. To a certain extent, ERS can promote the 
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restoration of ER function, and long-term ERS will destroy the stable state of cells, 
causing tissue damage and apoptosis [3]. The destruction of ER function and 
activation of apoptosis signaling pathways are the foundation of many 
neurodegenerative diseases, and one of the mechanisms of ischemia/reperfusion (I/R) 
injury [4]. 
Orexin-A (OXA) is a neuropeptide with neuroprotective effects against multiple 
stimuli. Intracerebroventricular injection of OXA into an experimental middle 
cerebral artery occlusion in rats can significantly reduce the volume of cerebral 
infarction [5]. Our laboratory has preliminarily confirmed that OXA has a 
neuroprotective effect against I/R injury in vivo [6] and against H2O2 damage in vitro 
[7]. We also found that ERS participates in engendering I/R injury [6,8], but that the 
neuroprotective effect of OXA occurs by inhibiting ERS has not been shown. 
Therefore, in the present study the oxygen-glucose deprivation and reoxygenation 
(OGD/R) of SH-SY5Y neuroblastoma cells was used as in vitro model of I/R injury to 
evaluate the protective effect of OXA on ERS-induced damage and the possible 
signaling pathways involved. Our aim was to explore the mechanism of the 
neuroprotective effect of OXA, and to provide the experimental basis for a new 
therapeutic approach for the clinical treatment of ischemic stroke.  
 
2. Materials and methods 
2.1 Chemicals and reagents 
Human OXA was obtained from Phoenix Pharmaceuticals (Belmont, CA, USA). 
Primary antibodies against GRP78, p-IRE1α, p-JNK, Cleaved caspase-3, Cleaved 
caspase-12, Bcl-2, and Bax were purchased from Cell Signaling Technology (Danvers, 
MA, USA). Anti-β-actin antibody was obtained from BZSGB Technology (Beijing, 
China). Suvareson (DORA), PI3K inhibitor LY294002 (LY) and Gi inhibitor pertussis 
toxin (PTX) were purchased from Sigma (St. Louis, MO, USA). Dulbecco’s modified 
Eagle’s medium (DMEM) and fetal bovine serum (FBS) were obtained from Gibco 
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Life Technologies (Grand Island, NY, USA).  
 
2.2 Cell culture 
The human neuroblastoma cell line SH-SY5Y, obtained from the Cell Resource 
Center Chinese Academy of Sciences (Shanghai, China), was cultured in DMEM with 
10% FBS, 100 U/mL penicillin, and 100 μg/mL streptomycin at 37°C in a humid 
atmosphere containing 5% CO2 and 95% air. SH-SY5Y cells were incubated in 96- or 
6-well plates, and used in subsequent experiments once the cells had grown to the 
appropriate concentration. 
 
2.3 OGD/R injury and experimental design 
To achieve I/R injury- like conditions in vitro, SH-SY5Y cells were treated with 
OGD/R [9]. Briefly, the cells were exposed to OGD conditions comprising culture in 
glucose-free medium in an atmosphere of <0.1% O2 in 5% CO2 and 95% N2 for 
several hours, after which they were returned to glucose-containing medium and 
cultured under the standard conditions of 95% O2 and 5% CO2 for several hours. To 
determine the appropriate degree of cell damage, the state of cells exposed to OGD 
followed by reoxygenation (R) conditions for different periods of time was evaluated. 
Treatment of SH-SY5Y cells with OGD for 4 h followed by reoxygenation for 4 h 
was determined to cause an appropriate I/R injury- like state, after which cells were 
treated with OXA. Studies [10,11] have shown that OXA acts via the G protein 
subunit Gi signaling pathway and PI3K signaling pathway; the effect of adding the 
inhibitor PTX or LY 30 minutes before OXA intervention was, therefore, also 
investigated. Each treatment group consisted of at least three replicates. 
 
2.4 Hematoxylin-eosin (HE) staining 
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HE staining was used to observe morphology after fixation of cultured SH-SY5Y 
cells. The covered slides with cells were washed thrice with phosphate-buffered saline 
(PBS), fixed in 95% alcohol for 15 minutes, and then washed twice in PBS for 1 
minute. Slides were stained with hematoxylin dye for 10 minutes then rinsed with 
running water, stained with differentiated solution for 30 seconds then rinsed with 
running water, and finally stained with eosin dye for 5 minutes then rinsed with 
running water. After staining, the cell climbing were dehydrated and transparent in 
sequence, and finally residence was dripped and fixed on the glass slide. 
 
2.5 Cell viability measurement 
The cell viability was measured using a Cell Counting Kit-8 (CCK-8) assay 
(KeyGEN BioTECH Corp., Nanjing, China) according to the manufacturer’s 
instructions. SH-SY5Y cells were cultured in 96-well plates at an initial density of 10 
× 104 per well. The incubation and treatment of cells were carried out according to the 
experimental requirements. CCK-8 reagent (10 μL) was added to each well and 
incubated for 2 h, after which the optical density (OD) at 450 nm wavelength was 
measured using a microplate reader (Bio-Rad, Hercules, CA, USA). All assays were 
repeated at least three times. 
 
2.6 Cell apoptosis measurement 
Apoptosis of SH-SY5Y cells was detected by flow cytometry with an Annexin 
V- FITC Apoptosis Detection Kit (KeyGEN BioTECH Corp.). According to the 
manufacturer’s instructions, the cells were repeatedly blown after being cleaved by 
trypsin and dispersed into single cells. After centrifugation, the cells were collected 
and washed twice with PBS, and suspended in Binding Buffer, and then 5 μL Annexin 
V-FITC and 5 μL propidium iodide were added and reacted in the dark for 15 minutes. 
After reaction, fluorescence was measured by flow cytometry (FACSCalibur; BD 
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Biosciences, Franklin Lakes, NJ, USA). All assays were repeated at least three times. 
 
2.7 Western blotting assay 
Protein extracted from the SH-SY5Y cell lysate was separated by SDS-PAGE, 
then transferred to a polyvinylidene fluoride membrane. After blocking with 5% milk 
for 1 h at room temperature, and washing with Tris Buffered saline Tween (TBST), 
the membrane was incubated with primary antibody at 4°C overnight. Following 
washing, the membrane was incubated at room temperature for 1 h with the 
corresponding secondary antibody labeled with horseradish peroxidase. Bands were 
revealed using an ECL kit according to the manufacturer’s instructions. Image 
processing and analysis were carried out with ImageJ2x software. 
 
2.8 RT-PCR 
Total RNA of SH-SY5Y cells from different treatment groups were extracted 
using Trizol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s 
instructions. The concentration of RNA was determined by A BioSpec-nano 
spectrophotometer (Shimadzu Corporation, Kyoto, Japan). Then, the cDNA was 
reverse transcribed using FastQuant cDNA first-strand synthesis kit (TIANGEN 
Biotechnology, Beijing, China) for PCR amplification. Amplification primers were 
synthesized by Biological Technology Co., Ltd. (Shanghai, China). Primer sequences 
were as follows: β-actin (human): forward: 5'-acactgtgcccatctacagggg-3', reverse: 5'-
atgatggagttgaaggtagtttcgtggat-3'; OX1R (human): forward: 5'-ttaagagggtgttcgggatg-3', 
reverse: 5'-actaggggccttcagagagc-3'. OX2R (human): forward: 5'-atttgggatgtttgcccata-
3', reverse: 5'-atggtgaactccaaggcaac-3'. The PCR reaction procedure was pre-
denaturation at 95 ℃ for 3 min, then 35 cycles of  95 ℃ for 30 s, 55 ℃ for 40 s, and 
72 ℃ for 40 s, followed by 72 ℃ for 10 min and 4 ℃ preservation. The productions 
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were detected by 1% agarose gel electrophoresis. Image processing and analysis were 
carried out with ImageJ2x software. 
 
 
2.9 Statistical analysis 
The experimental data were analyzed using GraphPad Prism 5 software, and the 
results are expressed as mean ± standard deviation. All data shown are representative 
of at least three independent experiments. Comparisons between two experimental 
groups were made by t-tests, and differences between groups were tested using a one-
way analysis of variance (ANOVA). Multiple comparison between the groups was 
performed using S-N-K method; p<0.05 was considered significant. 
 
3. Results 
3.1. Determination of the optimal time point for OGD 
To determine the optimal duration of oxygen and glucose deprivation for 
modeling ischemic injury in vitro, SH-SY5Y cells were deprived of oxygen and 
glucose for 2 h (OGD 2 h), 4 h (OGD 4 h), 8 h (OGD 8 h), 12 h (OGD 12 h), and 24 h 
(OGD 24 h). Microscopy and HE staining were used to observe cell morphology. As 
shown in Figure 1, SH-SY5Y cells cultured under normal conditions had clearly 
defined round or oval shaped nuclei, and abundant cytoplasm. After OGD treatment, 
the morphology changed, showing cell shrinkage and prominent protuberances (Fig. 
1A). HE staining revealed the cells to be spindle shaped or irregular, with little 
cytoplasm (Fig. 1B). Moreover, as the duration of OGD increased, the changes in cell 
morphology became more obvious. 
To determine the optimal time point for the OGD model, a CCK-8 assay was 
used to measure cell viability at the different time points. As shown in Figure 1C, 
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compared with the control group, the cell viability gradually decreased with 
increasing duration of OGD. Moreover, the cell viability of SH-SY5Y cells was 
significantly decreased at OGD 4 h (p<0.05), with a reduction of 17.7%, and the cell 
viability had decreased by 29.7% at OGD 8 h (p<0.05). Even by OGD 48 h, the cell 
survival rate had decreased by 56.5% (p<0.01). As a starting point for modeling 
reperfusion injury, and considering the injury effect of reperfusion, the optimal time 
point of OGD was determined as 4 h. 
 
3.2. Determination of the optimal time point for reoxygenation after OGD 
To determine the optimal time point for reoxygenation after OGD to model I/R 
injury in vitro, The SH-SY5Y cells were re-exposed to oxygen and glucose for 2 h (R 
2 h), 4 h (R 4 h), 8 h (R 8 h), 12 h (R 12 h), and 24 h (R 24 h). Microscopy and HE 
staining were used to observe cell morphology. After oxygen and glucose were 
restored, fluorescence microscopy demonstrated a change in cell morphology: the 
slender protrusions gradually disappeared, and the cell shape became blunt or tapered 
(Fig. 2A). HE staining showed that the cell morphology had recovered to normal, the 
number of cells had increased, and the boundary had blurred (Fig. 2B). 
The CCK-8 assay was also used to measure cell viability after restoring oxygen 
and glucose for different lengths of time after OGD 4 h. As shown in Figure 2C, after 
OGD 4 h, compared with the control group, the cell viability had decreased by 14.7% 
(p<0.05), and by 25.1% at OGD 4 h/R 4 h (p<0.05). The cell viability decreased more 
obviously as the reoxygenation time was increased. At R 24 h, the cell viability had 
decreased by 41.4% (p<0.001). Microscopy revealed that the number of cells 
increased during reoxygenation. After comprehensive consideration, the optimal 
timings for OGD/R were determined to be OGD 4 h/R 4 h, and these, denoted OGD/R 
hereafter, were used in all subsequent experiments. 
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3.3 OXA protects against OGD/R injury 
To determine whether OXA could alleviate the reduction in cell viability induced 
by OGD/R, the CCK-8 assay was used to detect viability in OGD/R-treated cells 
subsequently treated with OXA (OXA intervention group) or not. Compared with 
untreated cells (control group), the viability of SH-SY5Y cells was significantly 
decreased after OGD/R treatment (p<0.05), by about 22%. After OXA intervention, 
the cell viability increased significantly by 18.6% (p<0.05), compared with that of the 
OGD/R only-treated group (Fig. 3A). The results showed that OXA could indeed 
alleviate the decline in cell viability induced by OGD/R. 
To further clarify the protective effect of OXA on OGD/R-induced SH-SY5Y 
cell damage, flow cytometry was used to detect apoptosis. Compared with the control 
group, the apoptosis rate in the OGD/R group significantly increased by about 26.1% 
(p<0.05), while the apoptosis rate in the OXA intervention group decreased by about 
18.2% (p<0.05), compared with the OGD/R only-treated group (Fig. 3B). OXA is 
therefore able to inhibit apoptosis induced by OGD/R damage. 
3.4. OXA inhibits ERS via Gi and PI3K signaling pathways 
3.4.1 OGD/R triggers ERS 
To evaluate whether ERS is involved in OGD/R-induced cell damage, the 
expression of ERS-related proteins was analyzed by Western blotting after OGD/R. 
As shown in Figure 4, compared with the control group, the expression of the ERS-
related proteins GRP78, p-IRE1α, p-JNK, Cleaved caspase-3, and Cleaved caspase-12 
significantly increased after OGD/R treatment (p<0.05 and p<0.01). Compared with 
the control group, the expression of the apoptosis-related protein Bax increased 
(p<0.05 and p<0.01), while the expression of the anti-apoptosis factor Bcl-2 
decreased (p<0.05). The results therefore demonstrated that OGD/R does indeed 
trigger ERS and apoptosis. 
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3.4.2 OXA reduces ERS  
Having confirmed that OGD/R causes changes in the expression of ERS-related 
and apoptosis-related proteins, we investigated the effect of OXA on these changes. 
Compared with cells treated with OGD/R alone, intervention with OXA significantly 
decreased the expression of GRP78, p-IRE1α, p-JNK, Cleaved caspase-3, and 
Cleaved caspase-12 (p<0.05). In addition, the expression of Bax decreased (p<0.05), 
and that of Bcl-2 increased (p<0.05; Fig. 5). Therefore, intervention with OXA can 
protect from ERS and apoptosis induced by OGD/R. 
 
3.4.3 OXA inhibits ERS via Gi and PI3K signaling. 
Having confirmed that OGD/R triggers apoptosis induced by ERS, and that OXA 
can inhibit ERS and apoptosis induced by OGD/R, we then used kinase inhibitors 
PTX and LY to elucidate signaling pathways involved in OXA activity. Compared 
with cells treated with OGD/R followed by OXA intervention alone, the results of 
Western blotting showed that the expression of GRP78, p-IRE1α, p-JNK, Cleaved 
caspase-3, and Cleaved caspase-12 in the PTX+OXA group and the LY+OXA group 
increased (p<0.05), the expression of Bax increased (p<0.05), and the expression of 
Bcl-2 decreased (p<0.05). This indicated that blocking either the Gi or the PI3K 
pathway influenced the activity of OXA. Meanwhile, compared with the OGD/R 
group without OXA, the expression of GRP78, p-IRE1α, p-JNK, Cleaved caspase-3, 
and Cleaved caspase-12 in the PTX+OXA and LY+OXA groups decreased (p<0.05), 
the expression of Bax decreased (p<0.05), and the expression of Bcl-2 increased 
(p<0.05; Fig. 6). The results indicate that OXA plays a neuroprotective role by 
blocking the Gi and PI3K pathways. 
 
3.5. OXA protects cells from OGD/R damage via Gi and PI3K signaling 
To determine the pathways through which OXA attenuates OGD/R-induced cell 
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damage, the CCK-8 assay was used to evaluate viability in OGD/R-treated cells with 
OXA intervention after PTX or LY treatment. As shown in Figure 7A, compared with 
the OGD/R group, the viability of the OXA intervention group was significantly 
increased by 17.2% (p<0.05). Meanwhile, compared with the OXA intervention group, 
cell viability in the PTX+OXA and LY+OXA groups decreased by 5.9% and 5.2%, 
respectively (p<0.05), which confirmed that blocking the Gi or the PI3K pathway had 
a specific effect on the action of OXA. Above all, OXA can act via either the Gi or the 
PI3K pathway. 
To further analyze the protective effect of OXA intervention after PTX and LY 
treatment, flow cytometry was used to detect apoptosis in cells damaged by OGD/R 
after adding PTX or LY. As shown in Figure 7B, compared with the OGD/R group, 
the apoptosis rate in the OXA intervention group was reduced by 18.9% (p<0.05). 
Compared with the OXA intervention group, the apoptosis rate of cells in the 
PTX+OXA group increased by 6.7% (p<0.05), and that of cells in the LY+OXA group 
increased by 8.3% (p<0.05), which indicated that the protective effect of OXA was 
weakened after PTX or LY had blocked the corresponding pathway. In summary, 
OXA appears to act via the Gi and PI3K pathways, and both pathways are required. 
 
3.6 Determination of OX1R and OX2R 
We have confirmed that the impact of orexin was mediated by Gi and PI3K 
activations. Further to demonstrate the specificity of these properties, the use of 
orexin antagonist as suvorexant (DORA) had be investigated. First, we used RT-PCR 
to investigate the expression of OX1R and OX2R in SH-SY5Y cells. As shown in 
Figure 8A, The expression of OX1R was significantly changed in the OGD/R process 
of SH-SY5Y cells, and the OGD 4h/R 4h group was significantly higher than the 
Control group (p<0.001). Moreover, OX1R expression increased first and then 
decreased. It can be seen from Fig 8B that the expression of OX2R is also 
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significantly changed, and the OGD 4h/R 4h group is significantly higher than the 
Control group (p<0.05), but it does not follow a certain rule to produce changes. 
On this basis, DORA and OXA co-treatment groups were added, and Western 
blotting was used to detect the changes of corresponding protein expression after 
DORA intervention.  As shown in Figure 9, the expression of GRP78, p-IRE1α, p-
JNK, Cleaved caspase-3, and Cleaved caspase-12 in the OXA+DORA group 
increased (p<0.01), the expression of Bax increased (p<0.01), and the expression of 
Bcl-2 decreased (p<0.01), compared with the OXA group. It is indicated that the 
protective effect of OXA cannot be exerted after the blocking of OX1R and OX2R, 
which is consistent with the traditional view that OXA needs to bind to corresponding 
receptors to exert its effect. 
 
4. Discussion 
ERS is implicated in I/R and ischemia-hypoxia injury, and the damaged cells 
generate stress protection measures through ERS itself. However, severe or persistent 
ERS activates apoptosis signaling pathways, induces cell apoptosis, and aggravates 
cerebral I/R injury. Studies have confirmed that ERS participates in I/R and OGD/R 
injury, suggesting that ERS plays an important role in cerebral I/R injury [12-14]. 
Inhibition of ERS after I/R injury could be used as a key therapeutic approach 
for neuroprotection. In the present study, we designed an in vitro model of 
cerebral I/R injury and found that expression of a key ERS protein GRP78 was 
increased after OGD/R, indicating that OGD/R could induce ERS. The 
phosphorylation level of proteins downstream GRP78, including PERK, IRE1α, and 
ATF6 was simultaneously investigated, but only p-IRE1α was increased, implying 
that OGD/R induces the IRE1α signaling pathway. JNK and caspase-12 downstream 
of IRE1α were also induced by OGD/R. Some studies have confirmed that caspase-12, 
one of the caspase family of proteases, is located in the ER and is activated by ERS 
[15], which in turn activates cytoplasmic caspase-3 [16], culminating in ERS-
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mediated apoptosis. In the present study, we also found caspase-3 to be induced by 
OGD/R. Based on our results, we consider that ERS-mediated apoptosis induced by 
OGD/R is mainly carried out through GRP78/IRE1α/JNK and 
GRP78/IRE1α/caspase-12/caspase-3 pathways, findings that help to elucidate the 
mechanism of ERS-mediated apoptosis (Fig. 8). 
OXA is a neuropeptide secreted by the hypothalamus and has many 
physiological functions. Previous studies have revealed that OXA can promote the 
survival of cultured neurons derived from rat cerebral cortex [17], providing new 
insights for OXA as a potential neuroprotective factor. Other studies have shown that 
the regulation of post-ischemic glucose intolerance by OXA suppresses cerebral 
ischemic neuronal damage, providing evidence of the neuroprotective effect of OXA 
[18,19]. Studies on OXA and I/R injury are now gathering pace. OXA has a protective 
effect on I/R-induced gastric mucosa injury by reducing neutrophil activation and 
lipid peroxidation [20]. In in vivo experiments, OXA has been confirmed to change 
the pathological mechanism of cerebral ischemia and have a neuroprotective effect 
[21]. Consistent with these reports, we also found in the present study that OXA was 
neuroprotective in the OGD/R model by inhibiting apoptosis and promoting viability. 
The mechanism via which OXA alleviates cerebral I/R injury, however, is currently 
unclear. It is well known that ERS is involved in cerebral I/R injury. Therefore, we 
hypothesized that in the OGD/R in vitro model of I/R injury the neuroprotective effect 
of OXA occurs through its reduction of ERS-mediated apoptosis. Consistent with this 
hypothesis, we found that OXA did indeed produce an anti-apoptosis effect by 
reducing the expression of members of the ERS-related signaling pathways 
GRP78/IRE1α/JNK and GRP78/IRE1α/caspase-3/caspase-12, which provides new 
mechanistic evidence of the neuroprotective effect of OXA. 
 Studies have shown that the Gi pathway [22,23] and Gq pathway [24-26] are 
involved in the action of OXA, and other signaling pathways such as cAMP, MAPK-
ERK1/2, PI3K/Akt, and JNK are also involved [25]. Further studies have confirmed 
that OXA plays a protective role in diseases and pathophysiological processes through 
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the PI3K/AKT pathway [27-29]. However, there is little research on how OXA 
protects against cerebral I/R injury. Since we showed in our initial experiments that 
OXA can protect against OGD/R-induced damage by inhibiting ERS-induced 
apoptosis, we hypothesized that OXA activates the Gi or the PI3K signaling pathway. 
Treatment with OXA after intervention with the Gi inhibitor PTX and the PI3K 
inhibitor LY in the in vitro OGD/R model revealed that the protective effect of OXA 
could be weakened after blocking each of the two pathways. Considering the 
complexity of physiological functions of cells and organisms, it is entirely possible. 
Whether other pathways are also involved now needs to be explored. 
In conclusion, OGD/R triggered ERS, while OXA intervention reduced the 
cellular damage induced by ERS. The use of inhibitors verified that the pathways 
involved in the neuroprotective effect of OXA in the OGD/R model were the Gi and 
the PI3K pathways. These findings provide a basis for further study of the role and 
mechanism of action of OXA, and for exploring a new potential therapeutic approach 
in the clinical treatment of I/R injury.  
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Fig. 1. Morphology and viability of OGD-treated SH-SY5Y cells at different time 
points. A. Morphological changes of cells treated with OGD were observed under 
microscope. B. The morphological changes after OGD were observed by HE staining. 
C. Cell viability was measured at different time points of OGD. Compared with the 
control group, the cells shrinkage and prominent protuberances and to be spindle 
shaped or irregular, with little cytoplasm. And the cell viability gradually decreased 
with increasing duration of OGD.  
Data are expressed as the mean ± standard deviation (n=3).  
*p<0.05, **p<0.01 compared with the control group. 
 
Fig. 2. Morphology and viability of SH-SY5Y cells at different time points of 
reperfusion after OGD 4 h. A. Morphological changes of cells treated with OGD/R 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 
were observed under microscope. B. The morphological changes after OGD/R were 
observed by HE staining. C. Cell viability was measured at different time points of 
reperfusion. Compared with the OGD 4 h group, the cell morphology had recovered 
to normal, the number of cells had increased, and the boundary had blurred, and the 
cell viability decreased more obviously as the reoxygenation time was increased. 
Data are expressed as the mean ± standard deviation (n=3).  
*p<0.05, ***p<0.001 compared with the control group; 
#p<0.05, ###p<0.001 compared with the OGD 4 h group.  
Fig. 3. The effects of OXA on cell viability and apoptosis after OGD/R.  A. Cell 
viability of the OGD/R and OXA intervention group was measured. B. Apoptosis was 
detected by flow cytometry. OXA could indeed alleviate the decline in cell viability 
induced by OGD/R and inhibit apoptosis induced by OGD/R damage. 
Data are expressed as the mean ± standard deviation (n=3).  
#p<0.05 compared with the control group; *p<0.05 compared with the OGD/R group. 
 
Fig. 4. Expression of ERS-related and apoptosis-related proteins detected by Western 
blotting. A. ERS-related proteins GRP78, p-IRE1α, p-JNK, Cleaved caspase-12, and 
Cleaved caspase-3.  B. Apoptosis-related proteins Bcl-2 and Bax.  
Compared with the control group, the expression of GRP78, p-IRE1α, p-JNK, 
Cleaved caspase-12, Cleaved caspase-3 and Bax increased after OGD/R treatment, 
and the expression of Bcl-2 decreased. 
Data are expressed as the mean ± standard deviation (n=3).  
*p<0.05, **p<0.01 compared with the control group. 
 
Fig. 5. Effect of OXA on the expression of ERS-related proteins detected by Western 
blotting. A. The expression levels of GRP78, p-IRE1α, p-JNK, Cleaved caspase-12, 
and cleaved caspase-3.  B. The expression levels of Bcl-2 and Bax. Compared with 
cells treated with OGD/R alone, intervention with OXA significantly decreased the 
expression of GRP78, p-IRE1α, p-JNK, Cleaved caspase-3, Cleaved caspase-12 and 
Bax, and Bcl-2 increased  
Data are expressed as the mean ± standard deviation (n=3). 
#p<0.05 compared with the control group; *p<0.05 compared with the OGD/R group. 
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Fig. 6. Protein expression after adding inhibitors detected by Western blotting. A.  The 
expression levels of GRP78, p-IRE1α, p-JNK, Cleaved caspase-12, and cleaved 
caspase-3. B. The expression levels of Bcl-2 and Bax. The expression of GRP78, p-
IRE1α, p-JNK, Cleaved caspase-3, Cleaved caspase-12 and Bax in the PTX+OXA 
group and the LY+OXA group increased, and the expression of Bcl-2 decreased. 
Data are expressed as the mean ± standard deviation (n=3). 
*p<0.05 compared with the OGD/R group; #p<0.05 compared with the OXA group. 
 
Fig. 7. Cell viability and apoptosis after treating with Gi and PI3K inhibitors. A. Cell 
viability after OXA intervention following PTX and LY treatment in the OGD/R 
model. B. Apoptosis detected by flow cytometry. Compared with the OXA 
intervention group, cell viability in the PTX+OXA and LY+OXA groups decreased, 
the apoptosis rate increased. 
Data are expressed as the mean ± standard deviation (n=3).  
*p<0.05 compared with the OGD/R group; #p<0.05 compared with the OXA group. 
 
Fig. 8. The expression of OX1R and OX2R at different time points of OGD/R in SH-
SY5Y cells. A. The expression of OX1R were detected by RT-PCR. B. The expression 
of OX2R were detected by RT-PCR. The expression of OX1R and OX2R was 
significantly changed compared with the Control group. 
Data are expressed as the mean ± standard deviation (n=3).  
*p<0.05, ***p<0.001 compared with the Control group. 
 
Fig. 9. Effect of DORA on the expression of ERS-related proteins detected by 
Western blotting. A. The expression levels of GRP78, p-IRE1α, p-JNK, Cleaved 
caspase-12, and cleaved caspase-3. B. The expression levels of Bcl-2 and Bax. The 
expression of GRP78, p-IRE1α, p-JNK, Cleaved caspase-3, Cleaved caspase-12 and 
Bax in the OXA+DORA group increased, and the expression of Bcl-2 decreased, 
compared with the OXA group. 
Data are expressed as the mean ± standard deviation (n=3). 
**p<0.01 compared with the OXA group. 
 
Fig. 10. Scheme of the mechanism of action of OXA. Treatment with OXA in the 
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OGD/R model attenuates apoptosis induced by ERS through the Gi and PI3K 
pathways. OGD/R leads to severe damage of ER function, and unfolded protein 
accumulates in the ER and activates IRE1α, an ERS sensor protein, to induce the ER 
response. IRE1α is triggered by dissociation of GRP78 from the ER lumenal domains. 
When ER function is seriously damaged, activation of the JNK and caspase-12 
pathways induces apoptosis. Moreover, through the Gi and PI3K pathways, OXA 
attenuates apoptosis induced by ERS. 
 
Highlights: 
 Our results indicate that OA has a neuroprotective effect on OGD/R-induced cell damage by 
inhibiting ERS-induced apoptosis through the combined action of Gi and PI3K signaling 
pathways. 
 These findings help to clarify the mechanism underlying the neuroprotective action of OA. 
 The result should aid the development of further candidate drugs, and provide a new 
therapeutic direction for the treatment of ischemic stroke.  
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